thank Thank Good our for morning, joining Lisa. you, everyone, and today. you call
We are out are time quarter articulating for we vision for been our that pleased some second XXXX bearing results have the now. Eagle that
portfolio that our Over our agreements the our developed so, we focused revenue building double last XXXX. and of have products, year we more through would on and than licensing expectation stated or a strategically launches in organically double acquisitions, out with earnings
are We achieving aspiration. that
share, our And first the outperformed $XXX In our already best came more in first full non-GAAP $X.XX double per fact, of for months, revenues have XXXX. In our exceeded our year. all revenues year earnings just six half million half already at XXXX XXXX XXXX than we of number. already
growth thereafter. main continue Our from here. also forecast XXXX XXXX our cash with largest we deploying in This at internal grow investors further bridge is that the level to sheet. significant that suggests our need our The for disconnect we objective will is in is balance without to
Let view. moments of our me the explain take few to point next
and combined $XXX reached sales PEMFEXY vasopressin XXXX half nearly First of million.
year quarters the for third and remain this expectations quite we Our fourth of are that profitable. will
cash debt. in acquisition of only million our after $XX outstanding And this June million plus $XX with receivables, Our XXXX. receivables $XX million Acacia. cash And XX, at in as of strong million is total we position $XXX of for have is
significant questions XXXX needed we ability we revenue to comes look use our from them. that those, step-up bring and such It revenue Eagle XXXX for to growth. We are grow and it on very confident rebased down us. that much a after springboard medicines go Eagle period earnings. the objective continues clear continue as The broaden of like would significant year and to earnings XXXX XXXX here, is posting that and be active who exciting our fact can does like. asked in for to an I make frequently for to XXXX where our depend Eagle what as further here XXXX do from to are EPS most are a growth and to is
have achieving beyond. growth next and very chance year good We of a
to On the upside, BYFAVO added year. our product we next LANDIOLOL and and mix have BARHEMSYS hopefully
to year-over-year. expect also grow PEMFEXY We
projections current and the XXXX. vasopressin some a lead lose On XXXX. all, lineup, strong us BENDEKA our today to downside, decline, expect in product our we'll will very in with royalty All
acquisition the achieve to the we opportunities As where achieve XXXX. today. from and mix for previously three in cash now CALXX, the AnalaR do this announced major and of pipeline we significant are a require and mentioned, we our growth in we the to need deployment goals. cash be morning, FULVESTRANT, growth to of and see have dramatic receivables, clear, we not potential $XXX Adding not a potential do To million
very see have the in growth step-up so it Let's achieved all and we significant on far but XXXX. earnings unfolds, revenue focused how are beyond we that
and to product benefits. a many Let's discuss PEMFEXY the detail. rest the We opportunities is PEMFEXY is unique the us. market further one new and of that with in developed
from our have of million. $XX first half embraced PEMFEXY evidenced customers Our as sales
matures, ALIMTA of is that This way use we reimbursed months cycle. to are to due of customers end six first their believe in this our the likely market through As year. generics are highly form the this life generic of the a many of
these starting will the Thereafter, of allow XXXX. quarter their of we first in to back demand customers transition PEMFEXY, to expect in the dynamics market the many
we believe than XXXX. XXXX had sell that will PEMFEXY in we today, in we of more As
and diversified hospital pharmaceutical of our supports Turning directly now Acacia, leading objective which stated business recent acquisition to our becoming company. a of our
extending we these a two with the of Eagle With closing BARHEMSYS hospital seeing chemical picked into life excitement differentiation. transaction, XXXXs, new two BYFAVO, compelling around patent FDA-approved meaningful and products. the products and up lot are commercially the of early with Both entities are
these only BARHEMSYS minutes prevention rescue addressable on the a spend $X.X is the is PONV U.S. me to we already providers fit approved We a FDA referred for think Let as sizable received of most for and PONV despite prophylaxis. and there through for first healthcare prophylaxis such institutions. billion. vomiting call the why BARHEMSYS same of is estimated who prophylaxis the of treatment total postoperative rescue also approved few by not antiemetic opportunity. have patients, The and and a and nausea in is strong and synergistic for annual of here walking market PONV. treatment
for of adults undergoing indicated XX procedures maintenance sedation less. procedural The second minutes product, and induction BYFAVO in lasting is or the
Here is the the $XXX million more in per the estimated market addressable in States. procedural year United sedation than
impressed cost integration, we positioning BARHEMSYS and with and and Acacia's perspective. previous the underinvested of As both plans In manpower our BYFAVO. from were the products we commenced two a view, were the
total who launched the accelerate look trajectory vision, acute years had in were demonstrating now full plans, these Acacia. revenue decision-makers approximately of XX prior we strength commercial to launched a We approximately to we $XXX of COVID were to products strength annual nearly team. spent prior commercial BYFAVO leading Head of potential critical acquisition retained have space, XX the over XX team Debra products XX now Eli Eagle's the access its that the In skills Debra and which advantage employees Additionally, into years look industry work our combined the and future of the approximately XX Acacia's experience having at environment to builds two was hospital her our limited. to are is to future launches as to members in immensely reviewing BARHEMSYS believe with Lilly individuals XX. difficult could growth at the potential our leadership individuals. of million. sales care brings and we of very of whom we Acacia realize we and And prescribers months. President, acquisition products. the and and the with the usage We Hussain, pharmaceutical the Vice leadership Eagle's next streams care. recently Commercial. complement Senior serve and key forward experience impressed peak and and BYFAVO BARHEMSYS welcomed of in as as our of U.S. commercial diversify Most strengthen to forward potentially
million. strong projections and a Now product feedback is sales, around approval LANDIOLOL turning to thereafter. drug give application we with for Together NCEs of the announced FDA, set and with us peak from approved new newly Based into BARHEMSYS to beta-blocker. care their BYFAVO, patent this of LANDIOLOL, on LANDIOLOL, FDA Japan. launch growth seeking soon mid-next just shy life $XXX approval going on of hospital, we submission with the June critical commercial in three a Europe would cardioselective X, ultra-short-acting with stage, year a an leading
Our from has We death In indicated results is hospital potential contribute be as later pneumonia, at to the anticipate XXXX. that cause medical an the neutralizes a strong. clinical year and of that leading simple start a severity to this groundbreaking of pipeline clinically is add-on body. trials of bacterial antibiotic the It is our treatment bacterial understanding established these pneumonia. opportunity CALXX in blockbuster terms, which severe being worldwide. developed CALXX believe very is We could toxins interim significantly well the toxin end and
we to their begin current clinicians treatment Importantly, what will will In be we to the fall, opening eventually clinical asks over CALXX pneumonia trial expect the add worldwide. sites XXX regimen.
our of strengthening of from XXXXs, of entity action a the described it add the that property Think This a of of is mix, intellectual breathing. AnalaR care with early simply new we stimulates pipeline. to mid-XXXXs is portfolio like molecule a with hospital into the patents. a our the with a including chemical Now business matter mechanism acute protection novel that strong ventilator. composition NCEs addition pharmacologic DNAXXX transaction broadens
problem our sales unmet and with This a of being example with imagine products We where our be for indications You to present in a has address community acute acquiring postoperative acne And worldwide three number marketing depression, We expand prevalence depression overdose At significant respiratory serve believe see severity; fit thereafter. program; and infants. patients products. it's advanced medical XXXX to is strategic AnalaR can specialized elected and to for approval organization. believe we the portfolio and strong, respiratory common another from extremely in forward would indications, condition drug prematurity, of development of depression. and have breathing a a represent most of we community valuable. that hospital will will potential needs respiratory these anesthesia to our suffering pipeline stimulate that millions increase preterm continues postoperative move in to overdose, targeted able tremendous drug of
greater detail it President Now the indications of Vice Greenberg, Affairs, over will initial me in targeted our about Mike Mike? let turn to explain ENAXXX. Medical who for Dr.
